Vuong HG, et al. - Researchers sought to assess the treatment efficacy or drug toxicity of sorafenib in the treatment of metastatic medullary thyroid carcinomas (MTCs). The meta-analyses included 8 trials with 101 metastatic MTCs. Outcomes revealed a modest effect of sorafenib treatment and for patients with metastatic MTCs who have failed other therapeutic regimens, this treatment might be a candidate treatment. The most commonly observed adverse effects comprised Hand-foot syndrome, diarrhea, alopecia, mucositis, skin rash, fatigue, and hypertension.